Last reviewed · How we verify
Archimedes Development Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Immediate release morphine sulphate | Immediate release morphine sulphate | phase 3 | Opioid analgesic | Mu-opioid receptor (μ-OR) | Pain management |
Therapeutic area mix
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Ajay Wasan, MD, Msc · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- Asbjørn Mohr Drewes · 1 shared drug class
- BioDelivery Sciences International · 1 shared drug class
- Boston Children's Hospital · 1 shared drug class
- Brigham and Women's Hospital · 1 shared drug class
- AdventHealth · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Archimedes Development Ltd:
- Archimedes Development Ltd pipeline updates — RSS
- Archimedes Development Ltd pipeline updates — Atom
- Archimedes Development Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Archimedes Development Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/archimedes-development-ltd. Accessed 2026-05-14.